Title: Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20180901
Title: Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.
Journal: Oncotarget 20171226
Title: mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection.
Journal: Virology 20140301
Title: Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.
Journal: Bioorganic & medicinal chemistry letters 20130301
Title: TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO.
Journal: Cell metabolism 20120502
Title: Mammalian autophagy: core molecular machinery and signaling regulation.
Journal: Current opinion in cell biology 20100401
Title: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.
Journal: Nature 20090716
Title: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.
Journal: Current biology : CB 20040727
Title: Regulation of longevity and stress resistance by Sch9 in yeast.
Journal: Science (New York, N.Y.) 20010413
Title: Guichard SM, et al. AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules. Mol Cancer Ther. 2015 Nov;14(11):2508-18.
